Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lovastatin and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (LAPP)
NCT06636734Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lovastatin, pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Emory University. Started Dec 2024; status: recruiting.
02
Drugs
lovastatinpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06636734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636734.